AstraZeneca Signs US$1.2 B RNA Modification Partnership with Accent Therapeutics
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)
Published: 11 Jun-2020
DOI: 10.3833/pdr.v2020.i6.2543 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Building on its oncology presence, AstraZeneca has partnered with Accent Therapeutics on targeting RNA-modifying proteins (RMPs) for the treatment of cancer in a deal worth up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS